Stock Events

Stock Events

Camurus AB 

$48.39
31
-$6.61-12.02% Friday 18:51

Statistics

Day High
55
Day Low
55
52W High
71.07
52W Low
52.31
Volume
200
Avg. Volume
15
Mkt Cap
2.9B
P/E Ratio
55.91
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 22
$0.29
May 21
$0.28
May 21
$1,680
May 21
$0.07
May 21
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.15
0.25
0.34
0.43
Expected EPS
0.376698807
Actual EPS
N/A

Financials

33.23%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
678.51MRevenue
225.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CAMRF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc develops extended-release injectable and oral products for the treatment of prevalent and chronic diseases, similar to Camurus' focus on long-acting injectable treatments for various conditions.
Indivior Pharmaceuticals
INDV
Mkt Cap3.67B
Indivior PLC specializes in developing medications for addiction and serious mental illnesses, competing directly with Camurus' treatments in the opioid dependence sector.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited, a larger generic and specialty pharmaceutical company, competes across several areas, including the development of treatments for disorders that Camurus also targets.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the development of innovative treatments for disorders in areas such as psychiatry, where Camurus is also active.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, a global healthcare company, has a broad portfolio that includes treatments for neurological conditions, directly competing with some of Camurus' therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. operates in various therapeutic areas, including those targeted by Camurus, making it a competitor in the pharmaceutical and biotech space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. competes with Camurus through its comprehensive portfolio in areas like neuroscience, where Camurus also operates.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers products in various therapeutic areas, including infectious diseases and oncology, competing with Camurus' research and development in similar fields.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company has a diverse portfolio in areas like immunoscience, which could overlap with Camurus' work in developing treatments for complex diseases.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc, with its focus on pharmaceuticals, vaccines, and consumer healthcare, competes in the broader healthcare market, including areas targeted by Camurus.

About

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Show more...
CEO
Mr. Fredrik Tiberg
Employees
238
Country
SE
ISIN
SE0007692850

Listings

LSE
GB
0RD1.LSE
ST
SE
CAMX.ST
OTC Link
US
CAMRF
F
DE
7CA.F

0 Comments

Share your thoughts

FAQ

What is Camurus AB stock price today?▼
The current price of CAMRF is $48.39 USD — it has decreased by -12.02% in the past 24 hours. Watch Camurus AB stock price performance more closely on the chart.
What is Camurus AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Camurus AB stocks are traded under the ticker CAMRF.
What is Camurus AB market cap?▼
Today Camurus AB has the market capitalization of 2.9B
When is the next Camurus AB earnings date?▼
Camurus AB is going to release the next earnings report on May 12, 2026.
What were Camurus AB earnings last quarter?▼
CAMRF earnings for the last quarter are 0.18 USD per share, whereas the estimation was 0.26 USD resulting in a -29.45% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Camurus AB revenue for the last year?▼
Camurus AB revenue for the last year amounts to 678.51M USD.
What is Camurus AB net income for the last year?▼
CAMRF net income for the last year is 225.5M USD.
Does Camurus AB pay dividends?▼
Yes, CAMRF dividends are paid annual. The last dividend per share was 0.29 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Camurus AB have?▼
As of March 15, 2026, the company has 238 employees.
When did Camurus AB complete a stock split?▼
Camurus AB has not had any recent stock splits.
Where is Camurus AB headquartered?▼
Camurus AB is headquartered in Lund, SE.